| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6110166 | Journal of Hepatology | 2009 | 10 Pages |
Abstract
The combination of a histone deacetylase inhibitor with doxorubicin may be a novel and promising therapeutic modality for HCCs, particularly for SULF1-expressing HCCs.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Jin-Ping Lai, Dalbir S. Sandhu, Catherine D. Moser, Sophie C. Cazanave, Abdul M. Oseini, Abdirashid M. Shire, Viji Shridhar, Schuyler O. Sanderson, Lewis R. Roberts,